Changes in Attentional Control After a Focal Seizure.
Launched by UNIVERSITY HOSPITAL, LILLE · Jun 13, 2024
Trial Information
Current as of November 13, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how attention control changes after a focal seizure in patients with epilepsy. Researchers believe that when a specific area of the brain has a seizure, it may disrupt the networks that help us focus and pay attention. By observing these changes, the study aims to better understand the effects of seizures on cognitive abilities, which are often impacted in people with epilepsy.
To participate in this study, individuals must be between 18 and 80 years old and have focal epilepsy, which means their seizures start in a specific area of the brain. They should also have normal cognitive performance and be able to give informed consent. Participants can expect to stay in the hospital for about five days for a thorough evaluation and monitoring of their seizures and attention abilities. It’s important to note that those who are pregnant, unable to give consent, or have certain legal restrictions will not be eligible for the study. This research could help improve our understanding of how seizures affect attention and lead to better care for patients with epilepsy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age superior to 18 and under 80
- • Focal epilepsy with indication to pre-surgery work-up and 5 days programmed hospitalization dedicated to this work-up
- • Normal global cognitive performance (standard progressive Raven matrices score \> 5th percentile)
- • Be affiliated to the social security system
- • Have signed an informed consent
- Exclusion Criteria:
- • Pregnancy or breastfeeding
- • Not able to give consent (Article 1121-8 of the CSP)
- • Vulnerable person
- • Being deprived of liberty by judicial or administrative decision (Article L 1121-6 of the CSP)
- • Guardianship
- • Have a high probability of not respecting the protocol or of abandoning the study
- • Absence of any epileptic seizure recorded during the hospitalization
- • Recurrent seizures preventing the recording of at least 24 hours without any seizure following a seizure.
About University Hospital, Lille
University Hospital Lille is a leading academic medical institution dedicated to advancing healthcare through innovative clinical research and patient-centered care. As a prominent sponsor of clinical trials, the hospital leverages its extensive resources, multidisciplinary expertise, and state-of-the-art facilities to facilitate groundbreaking studies across various medical fields. Committed to enhancing therapeutic options and improving patient outcomes, University Hospital Lille collaborates with researchers, healthcare professionals, and industry partners to ensure rigorous scientific standards and ethical practices in all clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lille, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported